{
  "id": 10110809,
  "title": "OnKure Therapeutics CFO Jason Leverone sells $898 in stock",
  "url": "https://urgent.news/2026/09/27/onkure-therapeutics-cfo-jason-leverone-sells-898-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-27T01:31:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/onkure-therapeutics-cfo-jason-leverone-sells-898-in-stock-93CH-4918690"
  },
  "original_language": "en",
  "account": "OnKure Therapeutics CFO Jason Leverone sold 302 shares of the company's Class A Common Stock on September 21, 2026, for a total of $898. The shares were sold at prices ranging from $2.95 to $3.06, with an average sale price of $2.9742 per share. Currently, OnKure's stock is trading at $2.90, down 27% over the past six months and close to its 52-week low of $2.23. Analysts have price targets ranging from $11 to $21, suggesting the stock could be undervalued at its present level. Leverone made this sale to satisfy tax obligations related to the vesting of restricted stock units (RSUs) under the Issuer’s 2023 RSU Equity Incentive Plan. After the transaction, he owns 18,500 shares of the company's Class A Common Stock. H.C. Wainwright recently lowered its price target for OnKure Therapeutics Inc. to $21 from $27, while maintaining a Buy rating. This adjustment comes in response to preclinical data presented by the company for its pan-mutant PI3Kα inhibitors, OKI-345 and OKI-355. These compounds showed significantly greater cellular selectivity in certain cell lines compared to competitors like Eli Lilly’s tersolisib and Relay Therapeutics’ zovegalisib, highlighting the company's ongoing efforts to strengthen its therapeutic pipeline. This development could influence investors' perceptions of OnKure's financial outlook as they assess the company's evolving product lineup.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "OnKure Therapeutics president and CEO Saccomano sells $258 in stock",
        "url": "https://urgent.news/2026/09/27/onkure-therapeutics-president-and-ceo-saccomano-sells-258-in-stock",
        "published": "2026-09-27T01:46:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}